JINESH DEDHIA & ASSOCIATES COMPANY SECRETARIES

A-103, Raj Satyam CHS, Ashok Van, Shiv Vallabh Road, Dahisar (East), Mumbai-400068 Email Id:-jinesh@csjdedhia.in, Contact No.8108852470

Annual Secretarial Compliance Report of Marksans Pharma Limited For the year ended 31st March, 2022

We have examined:

- (a) all the documents and records made available to us and explanation provided by Marksans Pharma Limited ("The Listed Entity"),
- (b) the filings/ submissions made by the listed entity to the stock exchanges,
- (c) website of the listed entity,
- (d) any other document/ filing, as may be relevant, which has been relied upon to make this certification,

for the year ended 31st March, 2022 ("Review Period") in respect of compliance with the provisions of:

- (a) the Securities and Exchange Board of India Act, 1992 ("SEBI Act") and the Regulations, circulars, guidelines issued thereunder; and
- (b) the Securities Contracts (Regulation) Act, 1956 ("SCRA"), rules made thereunder and the Regulations, circulars, guidelines issued thereunder by the Securities and Exchange Board of India ("SEBI").

The specific Regulations, whose provisions and the circulars/ guidelines issued thereunder, have been examined, include:-

- (a) Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015;
- (b) Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018
- (c) Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
- (d) Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018 (Not Applicable during the review period);
- (e) Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2014 and The Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.
- (f) Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008 (Not Applicable during the review period);
- (g) Securities and Exchange Board of India (Issue and Listing of Non-Convertible and Redeemable Preference Shares) Regulations, 2013 (Not Applicable during the review period); and
- (h) Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015.

Based on the above examination, we hereby report that, during the Review Period:

(a) The listed entity has complied with the provisions of the above Regulations and circulars/guidelines issued thereunder.

- (b) The listed entity has maintained proper records under the provisions of the above Regulations and circulars/ guidelines issued thereunder in so far as it appears from my examination of those records.
- (c) The following are the details of actions taken against the listed entity/ its promoters/directors/ material subsidiaries either by SEBI or by Stock Exchanges (including under the Standard Operating Procedures issued by SEBI through various circulars) under the aforesaid Acts/ Regulations and circulars/ guidelines issued thereunder:

C	Action	Details of	Details of action	Observations/ Damaria	
Sr. No.	taken by	violation		Observations/ Remarks of the Practicing	
INU.	taken by	Violation	taken E.g. fines, warning letter,	Company Secretary, if	
			debarment, etc.	- ,	
1.	BSE	Non-compliance of	BSE vide its letter	The Company has made	
1.	Limited	Regulation 17 (1)	dated August 20,	The Company has made written representations	
	(BSE)	(a) of SEBI (LODR)	2020 and	written representations before the Exchange vide	
	(DSE)	Regulations, 2015	November 17,	letter dated August 27,	
		in respect of the	2020 levied fine of	2020 and November 19,	
		non-appointment	INR 5,36,900/-	2020 and November 19, 2020 clarifying that due	
		of Independent	and INR	to Coronavirus pandemic	
		Woman Director	3,83,500/-	across the globe and	
		on the Board of the	respectively	lockdown restrictions in	
			under SEBI	the country, the business	
		Company.	Circular No.	operations were totally	
			SEBI/HO/CFD/	disrupted and further, the	
			CMD/CIR/P/202	Company had already	
			0/12 dated	initiated the process of	
			January 22, 2020.	appointment and	
			January 22, 2020.	identified a person for	
				appointment as an	
				independent woman	
				director on the Board and	
				consequently, the Board	
				of Director at their	
				meeting held on	
				September 03, 2020	
				appointed Dr. Meena	
				Rani Surana as an	
				independent woman	
				director effective from 4 th	
				September, 2020 and	
				thereby, requested the	
				Exchange for the waiver	
				of the fine. Based on the	
				representation made by	
				the Company, the	
				Exchange waived the fine	
				levied vide their email	
				dated May 10, 2021.	
2.	National	Non-compliance of	NSE vide its letter	The Company has made	
	Stock	Regulation 17 (1)	dated August 20,	written representation	
	Exchange	(a) of SEBI (LODR)	2020 and	before the Exchange vide	
	of India	Regulations, 2015	November 17,	its letters dated August	

Ltd (NSE)	in respect of the	2020 levied fine of	27, 2020, November 19,
Ltd (145L)	non-appointment	INR 5,36,900/-	2020 and December 23,
	of Independent	and INR	2020, clarifying that due
	Woman Director	3,83,500/-	to the Coronavirus
	on the Board of the	respectively	pandemic across the
	Company.	under SEBI	globe and lockdown
	Company.	Circular No.	restrictions in the
		SEBI/HO/CFD/	country, the business
		CMD/CIR/P/202	operations were totally
		0/12 dated	disrupted and further,
		January 22, 2020.	the Company had
		, , , , , , , , , , , , , , , , , , ,	already initiated the
			process of appointment
			and identified a person
			for appointment as an
			independent woman
			director on the Board and
			consequently, the Board
			of Director at their
			meeting held on
			September 03, 2020
			appointed Dr. Meena
			Rani Surana as an
			Independent Woman
			Director effective from 4th
			September, 2020 and
			thereby, requested the
			Exchange for the waiver
			of the fine.
			Whereas, the Exchange
			vide its letter dated June
			28, 2021, informed the
			Company that the request
			made by the Company
			for waiver of fine was
			duly placed before the
			relevant authority of the
			exchange and that the
			same has not been
			considered favorably by
			the authority and the
			Company was ordered to
			pay the fine to the
			Exchange in the manner
			specified in the letter.
			In view of the same, the
			Company has duly made
			the payment of fine to the
			Exchange on July 01, 2021
			though maintained it as
			"under protest" and
			requested the Exchange

		to re-consider the matter	
		of waiver of fine. The said	
		request for waiver is	
		pending before the	
		Exchange as on March 31,	
		2022.	

(d) The listed entity has taken the following actions to comply with the observations made in previous reports:

Sr. No.	Observations of the Practicing Company Secretary in the previous reports		Actions taken by the listed entity, if any	Comments of the Practicing Company Secretary on the actions taken by the listed entity
1.	Regulation 17 (1) (a) of SEBI (LODR) Regulations, 2015 states that Board of directors of the top 1000 listed entities shall have at least one Independent woman director by April 1, 2020.	2020-2021	The Company has appointed Independent Woman Director on Board w.e.f. September 04, 2020 as per Regulation 17 (1) (a) of SEBI (LODR) Regulations, 2015.	Complied

For Jinesh Dedhia & Associates Company Secretaries

Place: Mumbai Date: 26th May, 2022 Jinesh Dedhia Proprietor Peer Review Certificate No.:1914/2022

ACS:54731 CP. 20229

UDIN: A054731D000393146